← Product Code [LLH](/submissions/MI/subpart-c%E2%80%94microbiology-devices/LLH) · K041003 # IMMUNOCARD TOXINS A & B, MODEL 712050 (K041003) _Meridian Bioscience, Inc. · LLH · Aug 20, 2004 · Microbiology · SESE_ **Canonical URL:** https://fda.innolitics.com/submissions/MI/subpart-c%E2%80%94microbiology-devices/LLH/K041003 ## Device Facts - **Applicant:** Meridian Bioscience, Inc. - **Product Code:** [LLH](/submissions/MI/subpart-c%E2%80%94microbiology-devices/LLH.md) - **Decision Date:** Aug 20, 2004 - **Decision:** SESE - **Submission Type:** Traditional - **Regulation:** 21 CFR 866.2660 - **Device Class:** Class 1 - **Review Panel:** Microbiology ## Indications for Use ImmunoCard® Toxins A & B is a rapid, qualitative, horizontal-flow enzyme immunoassay (ElA) for detecting Clostridium difficile toxins A and B in human stool. This assay is used as an aid in the diagnosis of C.difficile-associated disease. ## Device Story ImmunoCard® Toxins A & B is a rapid, qualitative, horizontal-flow enzyme immunoassay (EIA) for detecting C. difficile toxins A and B in human stool. The test kit includes a chromatography strip membrane pad with immobilized monoclonal anti-Toxin A and goat polyclonal anti-Toxin B antibodies. The user dilutes a stool sample with Specimen Diluent and Enzyme Conjugate (antibodies to toxins A and B conjugated to horseradish peroxidase), then adds the mixture to the test device. During incubation, toxins bind to the conjugate; subsequent flow captures the toxin-conjugate complex at the TEST reaction port. A CONTROL port verifies proper sample flow and reagent activity. After washing and adding a substrate reagent (tetramethyl-benzidine and peroxide), the user visually reads the result. Development of a blue color in the TEST port indicates a positive result. The device is intended for use in clinical laboratories to assist in diagnosing C. difficile-associated disease, enabling rapid initiation of treatment and isolation precautions. No instruments are required. ## Clinical Evidence Clinical performance evaluated using 591 samples (prospective and retrospective) compared against cell cytotoxicity assay with neutralization. Prospective study (n=250) showed 93.1% sensitivity (95% CI: 87.1-98.9%) and 98.9% specificity (95% CI: 97.6-100%). Retrospective study (n=341) showed 100% sensitivity and 98.4% specificity (95% CI: 96.4-99.6%). ## Technological Characteristics Horizontal-flow enzyme immunoassay. Components: chromatography strip membrane, plastic frame, immobilized antibodies, horseradish peroxidase-labeled goat polyclonal antibodies. Detection limit: 3.0 ng/ml. Visual readout. No electronic or software components. ## Regulatory Identification A microorganism differentiation and identification device is a device intended for medical purposes that consists of one or more components, such as differential culture media, biochemical reagents, and paper discs or paper strips impregnated with test reagents, that are usually contained in individual compartments and used to differentiate and identify selected microorganisms. The device aids in the diagnosis of disease. ## Predicate Devices - Premier Toxins A & B (Meridian Bioscience, Inc.) - ImmunoCard Toxin A (Meridian Bioscience, Inc.) - C. difficile Tox A/B II (Techlab, Inc.) - Oxoid Clearview C. difficile Toxin A (Unipath, Ltd.) - ColorPAC Toxin A (Becton Dickinson) ## Submission Summary (Full Text) > This content was OCRed from public FDA records by [Innolitics](https://innolitics.com). If you use, quote, summarize, crawl, or train on this content, cite Innolitics at https://innolitics.com. > > Innolitics is a medical-device software consultancy. We help companies design, build, and clear FDA-regulated software and AI/ML devices, including [a 510(k)](https://innolitics.com/services/510ks/), [a De Novo](https://innolitics.com/services/regulatory/), [a SaMD](https://innolitics.com/services/end-to-end-samd/), [an AI/ML medical device](https://innolitics.com/services/medical-imaging-ai-development/), or [an FDA regulatory strategy](https://innolitics.com/services/regulatory/). {0} 510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION DECISION SUMMARY DEVICE ONLY TEMPLATE A. 510(k) Number: K041003 B. Purpose of Submission: For the detection of C. difficile toxins A & B in human stool C. Analyte: Clostridium difficile toxins A & B D. Type of Test: Horizontal-flow enzyme immunoassay E. Applicant: Meridian Bioscience, Inc. F. Proprietary and Established Names: ImmunoCard® Toxins A & B G. Regulatory Information: 1. Regulation section: 21 CFR Part 866.2660 Microorganism Differentiation and Identification 2. Classification: I 3. Product Code: LLH – Reagents, Clostridium difficile toxin 4. Panel: 83 Microbiology H. Intended Use: 1. Intended use(s): ImmunoCard® Toxins A & B is a rapid, qualitative, horizontal-flow enzyme immunoassay (EIA) for detecting Clostridium difficile toxins A and B in human stool. This assay is used as an aid in the diagnosis of C. difficile-associated disease. 2. Indication(s) for use: ImmunoCard® Toxins A & B is an in-vitro diagnostic qualitative enzyme immunoassay to detect the presence of Clostridium difficile toxins A and B in human stool. The assay is used as an aid in the diagnosis of C. difficile-associated disease. {1} Page 2 of 5 3. Special condition for use statement(s): For Prescription Use Only 4. Special instrument Requirements: Not applicable I. Device Description: The device consists of a chromatography strip membrane housed in a plastic frame with two sample ports and two reaction ports. The membrane carries immobilized antibodies to toxins A and B at the test reaction port and crude C. difficile toxin at the control reaction port. The enzyme conjugate consists of a blend of goat polyclonal antibodies to toxins A & B. The group specific antibodies are bound to horseradish peroxidase as an indicator in the test and control regions of the strip. J. Substantial Equivalence Information: 1. Predicate device name(s): Premier Toxins A & B, ImmunoCard Toxin A, ColorPac Toxin A, C. difficile Toxin A, C. difficile Tox A/B II. 2. Predicate K number(s): K993914, K55859, K980185, K955067, K003306 3. Comparison with predicate(s): | Similarities | | | | --- | --- | --- | | Item | Device | Predicates | | Intended use | an in vitro diagnostic product for the detection of C. difficile toxins in human stool | same | | Specimen type | Human stool | same | | technology | Enzyme Immunoassay | same | | Level of skill | Moderately complex | same | | | Differences | | | Item | Device | Predicates | | Limit of detection | 3.0 ng/ml of toxins A & B | ≥0.8-2.5 ng/ml | | Clinical sensitivity | 95.2% CI (90.9-99.1%) | 81-94.7% CI (72.4-97.5%) | | Clinical specificity | 98.5% CI (98.0-100%) | 96.7-100% CI (95.4-100%) | K. Standard/Guidance Document referenced (if applicable): CDRH Draft Guidance Document: "Review Criteria for Assessment of Laboratory Tests Directed at Assisting in the Diagnosis of C.dificile Associated Disease" for Industry and FDA Staff. L. Test Principle: A chromatographic membrane strip held in a plastic frame and is coated with immobilized antibodies to toxin A and B. The enzyme conjugate reagent consists of group specific antibodies to toxins A and B bound to horseradish {2} Page 3 of 5 peroxidase. The sample is diluted with specimen diluent and enzyme conjugate and the mixture is incubated for 5 minutes. During the incubation, molecules of toxin, if present, are bound to the anti-toxin antibodies of the conjugate. Following incubation, an aliquot of the mixture is added to each of the two sample ports and the test is incubated for an additional 5 minutes. During the second incubation the toxin-conjugate complex is separated from particulate matter as the fluid portion of the sample flows through the membrane to the test and control reaction ports. The toxin-conjugate complexes are then captured at the test reaction port by immobilized antitoxin in the reaction membrane. The second of the two reaction ports serves as an internal control. Both reaction ports are subsequently washed with wash reagent to reduce interference by contaminating proteins before substrate reagent is added. The reaction ports are incubated for an additional 5 minutes during which time the enzyme conjugate modifies the substrate reagent. If A & B toxins are present, the development of a blue color in the test reaction port indicates a positive test. In the control port, the anti-toxin antibodies of the conjugate bind directly to the immobilized toxin. The appearance of a blue color in the control reaction port indicates that sample was added, that reagents were active at the time of use and that proper sample migration occurred. Reactions are read visually. ## M. Performance Characteristics (if/when applicable): ### 1. Analytical performance: **a. Precision/Reproducibility:** The reproducibility of ImmunoCard® Toxins A & B was determined with known negative (n=2) and positive (n=6) samples that were coded and randomly sorted to prevent their identification during testing. Two of the positive samples were near the limit of detection for the assay. Three laboratories tested the samples on three consecutive days. The samples produced the expected results 100% of the time. **b. Linearity/assay reportable range:** Not applicable **c. Traceability (controls, calibrators, or method):** Not applicable **d. Detection limit:** The ImmunoCard® Toxins A&B test kit detects toxins A & B at levels of 3.0 ng/ml. **e. Analytical specificity:** Stool specimens inoculated with the following microbial agents (to a final sample concentration of ≥ 10⁸ organisms/mL) do not react with ImmunoCard® Toxins A and B: Adenovirus 40, Adenovirus 41, Aeromonas hydrophila, Bacillus cereus, Bacillus subtilis, {3} Page 4 of 5 Bacteroides fragilis, Campylobacter coli, Campylobacter jejuni, Candida albicans, Clostridium butyricum, nontoxigenic C. difficile (10 strains), Clostridium perfringens, Clostridium septicum, Clostridium sordellii strain VPI9048, Clostridium sporogenes, Enterobacter cloacae, Escherichia coli (four strains including two O157:H7 strains), Helicobacter pylori, Klebsiella pneumoniae, Peptostreptococcus anaerobius, Porphyromonas asaccharolytica, Proteus vulgaris, Pseudomonas aeruginosa, Rotavirus, Salmonella typhimurium, Serratia liquefaciens, Shigella dysenteriae, Shigella flexneri, Shigella sonnei, Staphylococcus aureus, Staphylococcus aureus Cowan I, Staphylococcus epidermidis, Streptococcus faecalis, Vibrio parahaemolyticus, Yersinia enterocolitica. The only non-C. difficile microorganism reactive with ImmunoCard® Toxins A & B was Clostridium sordellii VPI 9714. This strain produces toxin A and B homologs HT and LT. An interference study was conducted and the following substances were determined to have no effect on test results when present in stool in the concentrations indicated: fecal fat (4.8% w/v), whole blood (40% v/v), mucin (3.5% w/v), Metronidazole (0.25% w/v), Vancomycin (0.25% w/v), barium sulfate (5% w/v), Imodium AD® (5% w/v), Kaopectate® Caplets (5 mg/mL) Pepto Bismol® (5% v/v). f. Assay cut-off The assay was determined to detect Toxin A and Toxin B at 3.0 ng/ml. 2. Comparison studies: a. Method comparison with gold standard: Three independent laboratories tested specimens with ImmunoCard® toxins A&B and the standard cell cytotoxicity assay with neutralization. The results of the parallel tests are given below. | Prospective Samples | ICTAB | | | | --- | --- | --- | --- | | | Pos | Neg | Total | | Cytotoxin Pos (Std) | 67 | 5 | 72 | | Cytotoxin Neg (Std) | 2 | 176 | 178 | | Total | 69 | 181 | 250 | | | | | 95% CI | | --- | --- | --- | --- | | Clinical sensitivity | 67/72 (93.1%) | | 87.1-98.9% | | Clinical specificity | 176/178 (98.9%) | | 97.6-100% | | Predictive value positive test | 67/69 (97.1%) | | 92.9-100% | | Predictive value negative test | 176/181 (97.2%) | | 94.5-99.5% | | | | | | | | | --- | --- | --- | --- | --- | --- | | Retrospective Samples | | ICTAB | | | | | | | Pos | Neg | Total | | | Cytotoxin Pos (Std) | | 33 | 0 | 33 | | | Cytotoxin Neg (Std) | | 5 | 303 | 308 | | {4} Page 5 of 5 | Total | | 38 | 303 | 341 | | --- | --- | --- | --- | --- | | | | | | 95% CI | | Clinical sensitivity | 33/33 (100%) | | | N/A | | Clinical specificity | 303/308 (98.4%) | | | 96.4-99.6% | | Predictive value positive test | 33/38 (86.8%) | | | 76.2-97.8% | | Predictive value negative test | 303/303 (100%) | | | N/A | b. Matrix comparison: Not applicable 3. Clinical studies: a. Clinical sensitivity: Two independent laboratories and Meridian’s Development Laboratory performed testing on archival (retrospective) or fresh (prospective) samples collected from symptomatic patient samples that had been submitted for toxin testing. The study included a minimum of 100 cytotoxin positive specimens and 75 cytotoxin negative specimens. The status of all samples (whether positive or negative by ImmunoCard) was confirmed by cytotoxin and neutralization. Less than 2% of the 591 samples tested were from pediatric patient (≤ 15 years). (See table above) b. Clinical specificity: Refer to (a.) above c. Other clinical supportive data (when a and b is not applicable): Not applicable 4. Clinical cut-off: The lower limit of detection of this assay is approximately 3 ng of toxin A and 3 ng of Toxin B per mL of stool. This limit does not vary from solid to liquid/semi-solid stool. 5. Expected values/Reference range: (Interpretive Criteria) The frequency of antibiotic-associated diarrhea caused by C. difficile is dependent on several factors including patient population, type of institution and epidemiology. The reported incidence of C. difficile-associated disease in patients suspected of having antibiotic-associated diseases is 15-20%, although different facilities may find positive rates above or below this range. A positive result in an uninfected patient is not expected. N. Conclusion: The submitted information in this premarket notification is complete and supports a substantial equivalence decision. --- **Source:** [https://fda.innolitics.com/submissions/MI/subpart-c%E2%80%94microbiology-devices/LLH/K041003](https://fda.innolitics.com/submissions/MI/subpart-c%E2%80%94microbiology-devices/LLH/K041003) **Published by [Innolitics](https://innolitics.com)** — a medical-device software consultancy. We help companies design, build, and clear FDA-regulated software and AI/ML devices. If you're preparing [a 510(k)](https://innolitics.com/services/510ks/), [a De Novo](https://innolitics.com/services/regulatory/), [a SaMD](https://innolitics.com/services/end-to-end-samd/), [an AI/ML medical device](https://innolitics.com/services/medical-imaging-ai-development/), or [an FDA regulatory strategy](https://innolitics.com/services/regulatory/), [get in touch](https://innolitics.com/contact). **Cite:** Innolitics at https://innolitics.com